145 related articles for article (PubMed ID: 8154647)
1. Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Lee KL; Califf RM; Simes J; Van de Werf F; Topol EJ
Ann Intern Med; 1994 May; 120(10):876-81; discussion 882-5. PubMed ID: 8154647
[TBL] [Abstract][Full Text] [Related]
2. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
[TBL] [Abstract][Full Text] [Related]
4. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
[TBL] [Abstract][Full Text] [Related]
6. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM
Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348
[TBL] [Abstract][Full Text] [Related]
7. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Langer A; Krucoff MW; Klootwijk P; Veldkamp R; Simoons ML; Granger C; Califf RM; Armstrong PW
J Am Coll Cardiol; 1995 Jun; 25(7):1552-7. PubMed ID: 7759706
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
[TBL] [Abstract][Full Text] [Related]
10. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries.
Singh N; Mironov D; Armstrong PW; Ross AM; Langer A
Circulation; 1996 Apr; 93(7):1388-95. PubMed ID: 8641028
[TBL] [Abstract][Full Text] [Related]
11. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators.
Califf RM; White HD; Van de Werf F; Sadowski Z; Armstrong PW; Vahanian A; Simoons ML; Simes RJ; Lee KL; Topol EJ
Circulation; 1996 Sep; 94(6):1233-8. PubMed ID: 8822974
[TBL] [Abstract][Full Text] [Related]
12. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
Hudson MP; Granger CB; Topol EJ; Pieper KS; Armstrong PW; Barbash GI; Guerci AD; Vahanian A; Califf RM; Ohman EM
Circulation; 2001 Sep; 104(11):1229-35. PubMed ID: 11551872
[TBL] [Abstract][Full Text] [Related]
13. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Holmes DR; Bates ER; Kleiman NS; Sadowski Z; Horgan JH; Morris DC; Califf RM; Berger PB; Topol EJ
J Am Coll Cardiol; 1995 Sep; 26(3):668-74. PubMed ID: 7642857
[TBL] [Abstract][Full Text] [Related]
14. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
GUSTO investigators
N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
[TBL] [Abstract][Full Text] [Related]
15. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.
Holmes DR; Califf RM; Topol EJ
J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):10S-17S. PubMed ID: 7775708
[TBL] [Abstract][Full Text] [Related]
16. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
Goel V; Naylor CD
Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
[TBL] [Abstract][Full Text] [Related]
17. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Mak KH; Moliterno DJ; Granger CB; Miller DP; White HD; Wilcox RG; Califf RM; Topol EJ
J Am Coll Cardiol; 1997 Jul; 30(1):171-9. PubMed ID: 9207639
[TBL] [Abstract][Full Text] [Related]
18. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.
Barradell LB; Goa KL
Pharmacoeconomics; 1995 Nov; 8(5):428-59. PubMed ID: 10172669
[TBL] [Abstract][Full Text] [Related]
19. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee.
Topol EJ; Armstrong P; Van de Werf F; Kleiman N; Lee K; Morris D; Simoons M; Barbash G; White H; Califf RM
J Am Coll Cardiol; 1992 May; 19(6):1123-8. PubMed ID: 1564212
[TBL] [Abstract][Full Text] [Related]
20. Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Tardiff BE; Califf RM; Morris D; Bates E; Woodlief LH; Lee KL; Green C; Rutsch W; Betriu A; Aylward PE; Topol EJ
J Am Coll Cardiol; 1997 Feb; 29(2):240-9. PubMed ID: 9014973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
